Abstract
Mosaic loss of Y chromosome (LOY) in leukocytes is associated with risk for death and disease in men. We investigated a polygenic risk score (PRS) for LOY comprising 156 previously associated germline variants, in 5131 men aged ≥70 years. Levels of LOY were estimated using microarrays and validated by whole genome sequencing. After adjusting for covariates, the PRS was a significant predictor of LOY (odds ratio 1.74). Men in the highest quintile of the PRS distribution had >5-fold higher risk of LOY than the lowest. A PRS for LOY could become a useful tool for risk prediction and targeted intervention.
Competing Interest Statement
L.A.F. is co-founder and shareholder in Cray Innovation AB.
Funding Statement
This work was supported by an ASPREE Flagship cluster grant (including the Commonwealth Scientific and Industrial Research Organisation, Monash University, Menzies Research Institute, Australian National University, University of Melbourne); and grants (U01AG029824 and U19AG062682) from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health, by grants (334047 and 1127060) from the National Health and Medical Research Council (NHMRC) of Australia, and by Monash University and the Victorian Cancer Agency. PL is supported by a National Heart Foundation Future Leader Fellowship (ID 102604). JM is supported by a NHMRC fellowship Leadership fellowship IG1173690. This work was supported by grants from the European Research Council (679744), the Swedish Research Council (2017-03762), the Swedish Cancer Society (20-1004) and Kjell och Marta Beijers Stiftelse to L.A.F.. Data handling and computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council (2018-05973), under the project SNIC (sens2019020).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent for genetic analysis was obtained, with ethical approval from the Alfred Hospital Human Research Ethics Committee (390/15) and site-specific Institutional Review Boards in the US
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-first authors
Data Availability
The data that support the findings of this study are available from the corresponding author upon request
